SPOTLIGHT: Codexis buys BioCatalytics

Codexis has acquired BioCatalytics, which makes enzymes that are employed to enhance chemical reactions. Codexis says the enzyme market should expand to $2.2 billion by 2010. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.